Risks for BIOSPECIFICS TECHNOLOGIES CORP (BSTC)

Here are some interesting risks from the recent filings of BIOSPECIFICS TECHNOLOGIES CORP. Our algorithms work hard to highlight risks unique to this company.

Our dependence upon revenue from Endo makes us subject to the commercialization and other risk factors affecting Endo over which we have limited or no control, including those risk factors identified by Endo in their 10-K for the year ended December 31, 2017, filed on February 27, 2018.

Endo may experience pricing pressure on the price of Endo’s products due to social or political pressure to lower the cost of drugs, which would reduce Endo’s revenue and future profitability.

Endo has limited experience in manufacturing biologic products and may encounter difficulties in Endo’s manufacturing processes, which could materially adversely affect Endo’s results of operations or delay or disrupt manufacture of those of Endo’s products that are reliant upon Endo’s manufacturing operations.